Abstract
The opioid system has been elucidated as a potential target for therapy in a variety of neurological disorders including stroke. Delta opioid receptors have been revealed to pose an especially compelling biological function for new neuroprotective therapies. Two distinct therapeutic mechanisms have been characterized for delta opioid receptors, namely, these receptors aid in maintaining ionic homeostasis and initiate endogenous neuroprotective pathways. Specific agonists of delta opioid receptors, such as (D-Ala2, D-Leu5) enkephalin (DADLE), have displayed the ability to promote neuronal survival and mitigate apoptotic pathways. These findings have led to a significant amount of research on this molecule’s potential as a neurotherapeutic. At the forefront of these efforts has been investigation into DADLE’s ability to protect neurons and glial cells following ischemia. Additionally, current research is attempting to reveal the dynamic neuroprotective mechanisms that mediate DADLE’s therapeutic benefits. This review article discusses the scientific evidence supporting the use of delta opioid family of receptors and ligands as a promising target for therapeutic intervention in neurological disorders, with emphasis on stroke.
Keywords: Brain diseases, (D-Ala2, D-Leu5) enkephalin (DADLE), Neurodegeneration, Neuroprotection, Opioids, Stroke, receptors.
CNS & Neurological Disorders - Drug Targets
Title:Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
Volume: 16 Issue: 4
Author(s): Marci G. Crowley, M. Grant Liska, Trenton Lippert, Sydney Corey and Cesar V. Borlongan*
Affiliation:
- Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B. Downs Blvd, Tampa, FL, 33612,United States
Keywords: Brain diseases, (D-Ala2, D-Leu5) enkephalin (DADLE), Neurodegeneration, Neuroprotection, Opioids, Stroke, receptors.
Abstract: The opioid system has been elucidated as a potential target for therapy in a variety of neurological disorders including stroke. Delta opioid receptors have been revealed to pose an especially compelling biological function for new neuroprotective therapies. Two distinct therapeutic mechanisms have been characterized for delta opioid receptors, namely, these receptors aid in maintaining ionic homeostasis and initiate endogenous neuroprotective pathways. Specific agonists of delta opioid receptors, such as (D-Ala2, D-Leu5) enkephalin (DADLE), have displayed the ability to promote neuronal survival and mitigate apoptotic pathways. These findings have led to a significant amount of research on this molecule’s potential as a neurotherapeutic. At the forefront of these efforts has been investigation into DADLE’s ability to protect neurons and glial cells following ischemia. Additionally, current research is attempting to reveal the dynamic neuroprotective mechanisms that mediate DADLE’s therapeutic benefits. This review article discusses the scientific evidence supporting the use of delta opioid family of receptors and ligands as a promising target for therapeutic intervention in neurological disorders, with emphasis on stroke.
Export Options
About this article
Cite this article as:
Crowley G. Marci, Liska Grant M., Lippert Trenton, Corey Sydney and Borlongan V. Cesar*, Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders, CNS & Neurological Disorders - Drug Targets 2017; 16 (4) . https://dx.doi.org/10.2174/1871527316666170320150659
DOI https://dx.doi.org/10.2174/1871527316666170320150659 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Cutaneous Adverse Reactions to Amoxicillin-Clavulanic Acid Suspension in Children: The Role of Sodium Benzoate
Current Drug Safety Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?
Combinatorial Chemistry & High Throughput Screening Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Macrophages in Immunopathology of Atherosclerosis: A Target for Diagnostics and Therapy
Current Pharmaceutical Design Pathogenesis of Central Nervous System Tuberculosis
Current Molecular Medicine Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry The Physicochemical and Pharmacokinetic Relationships of Barbiturates – From the Past to the Future
Current Pharmaceutical Design Diabetic Bone Fracture Repair: A Progenitor Cell-Based Paradigm
Current Stem Cell Research & Therapy Hyperglycemia-Related Pathophysiologic Mechanisms and Potential Beneficial Actions of Melatonin
Mini-Reviews in Medicinal Chemistry Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design Effects on Cytokines and Histology by Treatment with the Ace Inhibitor Captopril and the Antioxidant Retinoic Acid in the Monocrotaline Model of Experimentally Induced Lung Fibrosis
Current Pharmaceutical Design Nickel Allergy: Epidemiology, Pathomechanism, Clinical Patterns, Treatment and Prevention Programs
Endocrine, Metabolic & Immune Disorders - Drug Targets Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Features of Bioaccumulation and Toxic Effects of Copper (II) Oxide Nanoparticles Under Repeated Oral Exposure in Rats
Pharmaceutical Nanotechnology Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research